Phase 2RecruitingPriority 2 · High priorityNCT06698822
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
Plain-language summary
This trial is testing tofacitinib 2% cream applied to the skin for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
tofacitinib 2% cream (DRUG): Given topical
tofacitinib 2% cream
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details